{
    "clinical_study": {
        "@rank": "23542", 
        "acronym": "PERLES", 
        "arm_group": [
            {
                "arm_group_label": "Permixon\u00ae 160 mg & Placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Tamsulosine LP & Placebo", 
                "arm_group_type": "Other", 
                "description": "Active control arm"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating\n      subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using\n      Tamsulosine LP 0.4 mg as a reference treatment."
        }, 
        "brief_title": "PERmixon\u00ae in LUTS Evaluation Study (PERLES)", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Benign Prostatic Hyperplasia (BPH)", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subject\n\n          -  Between 45 and 85 years old\n\n          -  Subject with bothersome lower urinary tract symptoms (LUTS) due to BPH such as\n             frequency (daytime or night time), urgency, sensation of incomplete voiding, delayed\n             urination or weak stream\n\n          -  Subject naive to any prior treatment for LUTS due to BPH\n\n          -  Prostate enlargement at digital rectal examination (DRE) suggestive of BPH\n\n          -  I-PSS > 12 at enrolment visit and at inclusion visit\n\n          -  QoL I-PSS  score \u2265 3 evaluated at enrolment visit and at inclusion visit\n\n        Exclusion Criteria:\n\n          -  Urological history such as urethral stricture disease and/or bladder neck disease,\n             active (at enrolment and/or inclusion or recurrent urinary tract infection, stone in\n             bladder or urethra)\n\n          -  Any neurologic or psychiatric disease/disorder interfering with detrusor or sphincter\n             muscle\n\n          -  Insulin-dependent diabetes mellitus and non-controlled non insulin-dependent diabetes\n             mellitus\n\n          -  Known severe renal insufficiency or creatinine clearance < 30 ml/mn\n\n          -  Known liver insufficiency or clinically significant abnormal liver function tests\n\n          -  History of, or concomitant, cardiac arrhythmia or angina pectoris\n\n          -  Orthostatic hypotension at enrolment or inclusion visit\n\n          -  Known hypersensitivity to one of the constituents of the study drugs\n\n          -  Is participating in another clinical trial"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121613", 
            "org_study_id": "P00048 GP 4 04", 
            "secondary_id": "2014-000222-38"
        }, 
        "intervention": [
            {
                "arm_group_label": "Permixon\u00ae 160 mg & Placebo", 
                "description": "Oral administration - 160 mg twice daily.", 
                "intervention_name": "Permixon\u00ae 160 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tamsulosine LP & Placebo", 
                "description": "Oral administration - 0.4 mg daily.", 
                "intervention_name": "Tamsulosine LP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Permixon\u00ae 160 mg & Placebo", 
                    "Placebo", 
                    "Tamsulosine LP & Placebo"
                ], 
                "description": "Oral administration - twice daily.", 
                "intervention_name": "Placebo matching Permixon\u00ae 160 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Permixon\u00ae 160 mg & Placebo", 
                    "Placebo", 
                    "Tamsulosine LP & Placebo"
                ], 
                "description": "Oral administration - daily.", 
                "intervention_name": "Placebo matching Tamsulosine LP", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Permixon"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreuil Juigne", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Orens de Gameville", 
                        "country": "France"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seysses", 
                        "country": "France"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tierce", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "PERMIXON\u00ae 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia", 
        "overall_contact": {
            "email": "contact_essais_cliniques@pierre-fabre.com", 
            "last_name": "Pierre Fabre M\u00e9dicament"
        }, 
        "overall_official": {
            "affiliation": "Pierre Fabre Medicament", 
            "last_name": "Athmane BOUROUBI, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "Italy: The Italian Medicines Agency", 
                "Italy: Ethics Committee", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Ethics Committee", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "Czech Republic: Ethics Committee"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "I-PSS score change from baseline to D180", 
            "measure": "International Prostate Symptom Score (I-PSS score) change", 
            "safety_issue": "No", 
            "time_frame": "Day 180"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}